Gufic Biosciences Limited profit rises 40% in September

Gufic Biosciences Limited reported consolidated profit of Rs 23.4689 crore for the quarter ended September 30, 2026, up 40% from Rs 16.8240 crore a year earlier, as revenue from operations rose 22% to Rs 288.2730 crore. The unaudited results were approved by the board on November 14, 2026.

How did Gufic Biosciences perform in the September 2026 quarter?

Gufic Biosciences reported revenue from operations of Rs 288.2730 crore in the quarter ended September 30, 2026, compared with Rs 237.0545 crore in the quarter ended September 30, 2025. Total income, including other income, increased to Rs 289.3977 crore from Rs 239.1700 crore over the same period.

Consolidated profit before tax rose to Rs 31.4474 crore from Rs 22.6041 crore, while total tax expense increased to Rs 7.9788 crore from Rs 5.7815 crore. Consequently, profit for the period rose by Rs 6.6449 crore year on year to Rs 23.4689 crore from Rs 16.8240 crore.

Gufic Biosciences also reported a sequential increase from the quarter ended June 30, 2026, when revenue from operations was Rs 261.2780 crore and profit for the period was Rs 22.3128 crore. Revenue rose by Rs 26.9950 crore quarter on quarter and profit rose by Rs 1.1561 crore; basic and diluted earnings per share were Rs 2.34 in September 2026, against Rs 1.68 a year earlier.

What changed in Gufic Biosciences’ costs and profitability?

Gufic Biosciences’ consolidated total expenses increased to Rs 257.9503 crore in the September 2026 quarter from Rs 216.5659 crore a year earlier. This 19% increase was lower than the 21% rise in total income, resulting in profit before tax of Rs 31.4474 crore, compared with Rs 22.6041 crore in the corresponding quarter.

Cost of materials consumed rose to Rs 156.9236 crore from Rs 113.4716 crore, while employee-benefit expense increased to Rs 45.4288 crore from Rs 37.4506 crore. Finance cost was Rs 10.4396 crore versus Rs 9.5845 crore, depreciation and amortisation was Rs 7.7319 crore versus Rs 7.7730 crore, and other expenses were Rs 59.0277 crore versus Rs 57.3193 crore.

Based on the reported figures, Gufic Biosciences’ profit-for-the-period margin was about 8.1% of revenue from operations in September 2026, compared with about 7.1% in September 2025. This is a calculation from the reported results, not a management-provided margin; the company identified Pharmaceuticals as its sole operating segment and provided no product, geography or business-line split.

What do Gufic Biosciences’ half-year results show?

Gufic Biosciences reported consolidated revenue from operations of Rs 549.0910 crore for the half year ended September 30, 2026, compared with Rs 460.7770 crore in the corresponding half year of 2025. Consolidated profit for the six-month period increased to Rs 45.7817 crore from Rs 29.8944 crore.

Total income for the half year reached Rs 550.6732 crore, compared with Rs 463.8177 crore a year earlier, while total expenses increased to Rs 489.1864 crore from Rs 423.9395 crore. Profit before tax was Rs 61.4868 crore, up from Rs 39.8782 crore, and total tax expense rose to Rs 15.7054 crore from Rs 9.9852 crore.

The half-year increase in profit for the period was about 53%, exceeding the 40% rise recorded in the September quarter alone. Basic earnings per share for the half year were Rs 4.57, compared with Rs 2.98 in the half year ended September 30, 2025; diluted earnings per share were also Rs 4.57 versus Rs 2.98.

What do Gufic Biosciences’ balance sheet and cash flows show?

Gufic Biosciences had consolidated total assets of Rs 1,451.1723 crore as of September 30, 2026, compared with Rs 1,342.3740 crore at March 31, 2026. Inventories rose to Rs 372.2062 crore from Rs 324.4666 crore, while trade receivables increased to Rs 325.9737 crore from Rs 297.3967 crore during the six months.

Total consolidated equity increased to Rs 709.8205 crore at September 30, 2026 from Rs 664.9867 crore at March 31, 2026. Current borrowings rose to Rs 357.1912 crore from Rs 280.1269 crore, while non-current borrowings declined to Rs 92.2638 crore from Rs 105.0355 crore; cash and cash equivalents stood at Rs 65.2304 crore, compared with Rs 62.1859 crore.

Net cash generated from operating activities was Rs 5.1669 crore in the half year ended September 30, 2026, down from Rs 59.1152 crore a year earlier. The filing recorded negative working-capital movements of Rs 78.7258 crore, including a Rs 47.7396 crore increase in inventories and a Rs 30.0216 crore increase in receivables, while investing activities used Rs 42.8096 crore, including Rs 35.9516 crore for property, plant and equipment including capital advances.

Conclusion

Gufic Biosciences’ September-quarter results show profit growing faster than revenue, with consolidated profit increasing by Rs 6.6449 crore to Rs 23.4689 crore and revenue from operations rising by Rs 51.2185 crore to Rs 288.2730 crore. For the half year, profit increased by Rs 15.8873 crore to Rs 45.7817 crore while revenue increased by Rs 88.3140 crore to Rs 549.0910 crore.

The next reported results will indicate whether Gufic Biosciences can maintain this earnings progression while managing working capital and borrowings. At September 30, 2026, inventory was Rs 372.2062 crore, receivables were Rs 325.9737 crore and current borrowings were Rs 357.1912 crore; the filing does not disclose a separate financial target or operating plan beyond the reported results.